No, I don't think the lessons have been learned. This is a global issue, in the sense that access and affordability considerations are not being baked into the way that funding is being allocated for the development of things like vaccines and therapeutics.
One of the very clear lessons learned—and in fact, it's recommended in multiple reports from different parliamentary committees—is to include access and affordability provisions in funding agreements, in the funding provided for the development of vaccines and therapeutics, basically to say that if Canada is providing funding to develop a medicine, that medicine should be made affordable and accessible to Canadians and people around the world at reasonable and fair prices.
No, the lessons have not effectively been learned, and we continue to see massive inequity in access to things like vaccines, therapeutics and diagnostic tests in the places where we work.